Online inquiry

IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5126MR)

This product GTTS-WQ5126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL1RAP gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001167928.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3556
UniProt ID Q9NPH3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5126MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10894MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ3631MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ14075MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ1244MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ4378MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-188667
GTTS-WQ1837MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ2165MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ5507MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CDP4940
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW